Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Are novel outcome measures for Charcot-Marie-Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study.
Pazzaglia C, Padua L, Pareyson D, Schenone A, Aiello A, Fabrizi GM, Cavallaro T, Santoro L, Manganelli F, Coraci D, Gemignani F, Vitetta F, Quattrone A, Mazzeo A, Russo M, Vita G; CMT-TRIAAL Group. Pazzaglia C, et al. Among authors: santoro l. Neuromuscul Disord. 2019 Apr;29(4):310-316. doi: 10.1016/j.nmd.2019.01.009. Epub 2019 Feb 2. Neuromuscul Disord. 2019. PMID: 30926199
GDAP1 mutation in autosomal recessive Charcot-Marie-Tooth with pyramidal features.
Biancheri R, Zara F, Striano P, Pedemonte M, Cassandrini D, Stringara S, Manganelli F, Santoro L, Schenone A, Bellone E, Minetti C. Biancheri R, et al. Among authors: santoro l. J Neurol. 2006 Sep;253(9):1234-5. doi: 10.1007/s00415-006-0149-4. Epub 2006 Apr 10. J Neurol. 2006. PMID: 16607474 No abstract available.
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A, Vita G, Gemignani F, Visioli F, Solari A; CMT-TRIAAL Group. Pareyson D, et al. Among authors: santoro l. Pharmacol Res. 2006 Dec;54(6):436-41. doi: 10.1016/j.phrs.2006.09.001. Epub 2006 Sep 9. Pharmacol Res. 2006. PMID: 17029975 Clinical Trial.
Familial aggregation of white matter lesions in myotonic dystrophy type 1.
Di Costanzo A, Santoro L, de Cristofaro M, Manganelli F, Di Salle F, Tedeschi G. Di Costanzo A, et al. Among authors: santoro l. Neuromuscul Disord. 2008 Apr;18(4):299-305. doi: 10.1016/j.nmd.2008.01.008. Epub 2008 Mar 11. Neuromuscul Disord. 2008. PMID: 18337099
Nine-year case history of monofocal motor neuropathy.
Manganelli F, Pisciotta C, Iodice R, Calandro S, Santoro L. Manganelli F, et al. Among authors: santoro l. Muscle Nerve. 2008 Jul;38(1):927-9. doi: 10.1002/mus.21005. Muscle Nerve. 2008. PMID: 18508346
Case of acute motor conduction block neuropathy (AMCBN).
Manganelli F, Pisciotta C, Iodice R, Calandro S, Dubbioso R, Ranieri A, Santoro L. Manganelli F, et al. Among authors: santoro l. Muscle Nerve. 2009 Feb;39(2):224-6. doi: 10.1002/mus.21219. Muscle Nerve. 2009. PMID: 19145655
786 results